Semaglutide vs Tirzepatide vs Retatrutide: GLP-1 Research Comparison
A data-driven comparison of the three major GLP-1-based weight management compounds: mechanism differences, Phase 3 efficacy data, and side effect profiles.
The GLP-1 receptor agonist class has transformed obesity research over the past decade. Three compounds now dominate the field: semaglutide (dual GLP-1/GIP indirect), tirzepatide (GLP-1/GIP dual agonist), and retatrutide (GLP-1/GIP/glucagon triple agonist). Each represents a distinct pharmacological strategy, and the efficacy data tells a clear progression story.
The Receptor Landscape
Understanding the differences requires understanding what each receptor does:
GLP-1R (Glucagon-Like Peptide-1 Receptor)
- Stimulates insulin secretion (glucose-dependent)
- Reduces glucagon secretion
- Slows gastric emptying (produces satiety)
- Acts centrally on appetite-regulating hypothalamic neurons
- Reduces food reward signalling
GIPR (Glucose-Dependent Insulinotropic Polypeptide Receptor)
- Synergises with GLP-1R on insulin secretion
- Acts on adipose tissue to regulate lipid metabolism
- Central effects on appetite (controversial — may amplify GLP-1R signalling)
- Potentially reduces GI side effects of GLP-1 monotherapy
Glucagon Receptor
- Increases hepatic glucose output (typically undesirable in T2DM)
- Crucially: directly increases energy expenditure and lipolysis
- Reduces hepatic fat (NASH effects)
- Suppresses appetite via separate central mechanism
Semaglutide: The GLP-1 Benchmark
Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist with approximately 94% homology to native GLP-1 but engineered for a half-life of ~7 days via fatty acid conjugation. It is a monoagonist — it acts exclusively at GLP-1R.
STEP 1 Trial (NEJM 2021):
- 1961 participants, 68-week treatment
- 2.4mg weekly (subcutaneous)
- Mean weight loss: 14.9% body weight vs 2.4% placebo
- 86.4% of participants achieved ≥5% weight loss
Semaglutide set the first meaningful benchmark for pharmacological weight loss, decisively outperforming older agents like orlistat and phentermine/topiramate.
Tirzepatide: Dual Agonism Advantage
Tirzepatide (Mounjaro/Zepbound) is a single molecule that simultaneously agonises both GLP-1R and GIPR with approximately balanced potency at each receptor. This “twincretin” approach was designed to capture synergistic metabolic effects.
SURMOUNT-1 Trial (NEJM 2022):
- 2539 participants, 72-week treatment
- Three dose groups: 5mg, 10mg, 15mg weekly
- 15mg: Mean weight loss 22.5% vs 2.4% placebo
- 96.5% of 15mg group achieved ≥5% weight loss
- 63.6% achieved ≥20% weight loss at 15mg
The GIPR component appears to both amplify GLP-1R-mediated weight loss (synergistic central appetite suppression) and reduce nausea/vomiting compared to equivalent-efficacy GLP-1 doses. The improvement over semaglutide (~14.9% → ~22.5% at maximum dose) is substantial and statistically robust.
Retatrutide: Triple Agonism and the Glucagon Advantage
Retatrutide adds glucagon receptor agonism to the GLP-1/GIP combination. The glucagon component was the controversial design choice — glucagon typically raises blood glucose and has been viewed as a target to block in T2DM. However, at glucagon levels achievable with GLP-1/GIP co-agonism (which buffer the glucose-raising effect), glucagon’s energy expenditure and lipolytic effects become accessible.
Phase 2 Trial (NEJM 2023):
- 338 participants, 48-week treatment
- Maximum dose 12mg weekly
- 12mg: Mean weight loss 24.2% at 48 weeks
- Dose-response clearly demonstrated throughout study
- Hepatic fat reduction was notable (relevant for NASH/NAFLD)
The 48-week readout at 24.2% exceeds the tirzepatide 72-week benchmark (~22.5%), though cross-trial comparisons are inherently limited. Phase 3 data from the TRIUMPH program will provide definitive comparison.
Side Effect Profile Comparison
All three compounds share the GLP-1 class effect profile:
| Side Effect | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Nausea | ~44% | ~31% | ~42% |
| Vomiting | ~24% | ~16% | ~26% |
| Diarrhoea | ~30% | ~22% | ~24% |
| Constipation | ~24% | ~25% | ~19% |
| Discontinuation (GI) | ~4.3% | ~4.3% | ~3.0% |
Tirzepatide’s GIPR component appears to meaningfully reduce nausea and vomiting compared to semaglutide at equivalent weight loss. Retatrutide’s GI profile is similar to semaglutide.
Unique to retatrutide: Slight increase in heart rate (shared with GLP-1 class but potentially amplified by glucagon receptor activity). Phase 3 cardiovascular outcomes data will be critical.
The Research Trajectory
The progression is clear:
- GLP-1 alone (semaglutide): ~15% weight loss — pharmacological weight loss is viable
- GLP-1 + GIP (tirzepatide): ~22.5% weight loss — dual agonism adds meaningful efficacy
- GLP-1 + GIP + glucagon (retatrutide): ~24% at 48 weeks — triple agonism adds energy expenditure
The question the field is now asking: Is there a ceiling? At 24% weight loss, we are approaching the efficacy of bariatric surgery (~25-30%). Future compounds exploring additional receptor targets (amylin, NPY, CCK) may answer this.
All data cited is from published Phase 2/3 clinical trials. These compounds are research-stage peptides. This article is for educational purposes only.
Interested in the peptides discussed in this article?
Browse our full catalog of research-grade peptides or contact us for personalized recommendations.